Helixgate https://validator.w3.org/feed/docs/rss2.html Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers Home BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays Ketamine Triggers Sex-Specific Brain Recovery Responses Microbiota-Derived Metabolite Enhances HIV Therapy in Monkeys Lilly and Resilience invest $750M in diabetes and obesity drug device supply Novo setback casts doubt on a new way to treat heart disease Spatiotemporal Multiomics Charts Cellular Dynamics of Liver Metastasis Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy Replimune melanoma drug wins support of FDA panel Alnylam plunges as earnings deliver ‘one-two punch’ Capricor’s data clash and a fugitive in the C-suite A Computational Framework for Designing Disordered Proteins at Large Scale Replimune’s twice-rejected melanoma drug prevails in FDA adcomm FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices AbbVie shares pressured as Q2 I&I beat falls below investor expectations Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9% Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma Federal government could improve infectious disease monitoring, says federal government Opinion: What a recent op-ed got wrong about our Covid study Key Senate panel backs Trump’s picks for CDC, pandemic preparedness Judge denies states’ motion to postpone Medicaid work requirement STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts The lightbulb moment behind a potential antiviral breakthrough  Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate J&J secures right to take the helm in up to $925M Sail CAR T pact Ebola outbreak nears milestone, but vaccine is close  Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions Life after the lead asset: Advancing an early-stage pipeline STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption New funding, new jobs: 4 biotechs hiring after series B raises Not-so-special delivery: When biopharmas fumble layoff news Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store Is it safe to drink Red Bull and vodka? Questionable research tied to energy drink giant has shaped policy FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting Elix and University of Vienna Aim to Advance Drug Discovery Using AI NSF testing new Ph.D. model giving trainees academic and industry experience Capricor Duchenne cell therapy voted down by FDA panel Genetic Study of Fibromyalgia Points to Neurological Basis Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit ERAD-level gene switches for on-demand protein secretion and rapidly controlled gene therapies Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function